Search company, investor...
Search

Predict your next investment

BD company logo
Corporation
HEALTHCARE | Medical Equipment & Supplies
bd.com

See what CB Insights has to offer

Investments

10

Portfolio Exits

9

Partners & Customers

10

Service Providers

1

About BD

BD is a medical technology company that manufactures and sells a broad range of supplies, devices, and systems for use by healthcare professionals, medical research institutions, industry, and the general public. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

BD Headquarters Location

1 Becton Drive

Franklin Lakes, New Jersey, 07417,

United States

201-847-6800

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BD

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find BD in 4 Expert Collections, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

C

Conference Exhibitors

5,302 items

M

Medical Devices

4,400 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

H

Health Monitoring & Diagnostics

702 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

BD Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BD Rank

Latest BD News

Becton Dickinson and : BD Launches First-in-Human Trial of Sirolimus Drug-Coated Balloon to Expand Treatment Options for Peripheral Arterial Disease

Aug 18, 2022

08/18/2022 | 06:44am EDT Message : *Required fields First patient enrollment in PREVISION trial marks opportunity to further advance the safety and performance of drug-coated balloon technology and aligns with the company's commitment to developing innovations that enhance Chronic Disease Outcomes FRANKLIN LAKES, N.J., Aug. 18, 2022 - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has announced the start of enrollment in a first-in-human trial of a peripheral sirolimus drug-coated balloon (DCB). BD is a pioneer in DCB technology as the first to gain U.S. FDA approval for a paclitaxel DCB. BD's Lutonix™, which received FDA approval in 2014, is celebrating its 10-year anniversary globally this year. Over this time, BD has continued to innovate and lead in DCB technology with advancements such as additional indications, lower sheath profile, longer treatment lengths, and additional guidewire configurations. Today, DCBs remain a broadly accepted endovascular interventional treatment option for patients with peripheral arterial disease (PAD) of the femoropopliteal artery. "PAD impacts more than 200 million people across the globe and is often associated with morbidity, functional declines and higher health care costs.1 BD is committed to delivering much-needed solutions to address these challenges," said Paddy O'Brien, Worldwide President of BD Peripheral Intervention. "The launch of our PREVISION first-in-human study demonstrates our ongoing commitment to advancing the drug coated balloon category. It marks an important milestone on the path towards bringing this technology to clinicians and patients around the globe." The PREVISION trial is a prospective, multicenter, single arm, non-randomized study designed to evaluate the safety of the BD sirolimus DCB in the treatment of peripheral arterial disease in the femoropopliteal arteries. BD initiated this trial to determine the viability of sirolimus as a future treatment option for patients with PAD. The first patient was successfully treated by Dr. Andrew Holden, principal investigator at Auckland City Hospital, New Zealand. "It is an honor to enroll the first patient in the PREVISION study," said Dr. Holden. "The burden of PAD continues to impact patients and challenge physicians around the globe. A continued focus on developing next-generation technology is important for the patients suffering from PAD." PREVISION is being conducted across multiple sites in Australia, New Zealand, and Singapore. The trial will enroll and follow-up on approximately 50 patients over the coming months. 1 Fanaroff A, Rao S, Swaminathan R. Radial Access for Peripheral Interventions. Interventional Cardiolology Clinics. 2020;9:53-61. doi: https://doi.org/10.1016/j.iccl.2019.08.005 About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo . MEDIA CONTACT: INVESTOR CONTACT:

BD Investments

10 Investments

BD has made 10 investments. Their latest investment was in Islacare as part of their Corporate Minority on May 5, 2022.

CBI Logo

BD Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/13/2022

Corporate Minority

Islacare

Yes

1

8/16/2017

Series A

MedAware

$8M

Yes

3

2/23/2016

Series D

DiabetOmics

$4.8M

Yes

1

4/6/2015

Grant - II

Subscribe to see more

$99M

Subscribe to see more

10

11/16/2010

Series A

Subscribe to see more

$99M

Subscribe to see more

0

Date

5/13/2022

8/16/2017

2/23/2016

4/6/2015

11/16/2010

Round

Corporate Minority

Series A

Series D

Grant - II

Series A

Company

Islacare

MedAware

DiabetOmics

Subscribe to see more

Subscribe to see more

Amount

$8M

$4.8M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

3

1

10

0

BD Portfolio Exits

9 Portfolio Exits

BD has 9 portfolio exits. Their latest portfolio exit was embecta on April 01, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/1/2022

Spinoff / Spinout

embecta

$99M

2

10/25/2018

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

9/7/2018

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

2/15/2018

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

3/9/2016

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/1/2022

10/25/2018

9/7/2018

2/15/2018

3/9/2016

Exit

Spinoff / Spinout

Divestiture

Divestiture

Divestiture

Divestiture

Companies

embecta

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

BD Acquisitions

28 Acquisitions

BD acquired 28 companies. Their latest acquisition was MedKeeper on July 28, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/28/2022

$99M

Acquired

1

6/6/2022

$99M

Acquired - II

3

2/1/2022

Growth Equity

$99M

$3.02M

Acquired

8

12/21/2021

Other

Subscribe to see more

$99M

$99M

Subscribe to see more

10

12/9/2021

Other

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

7/28/2022

6/6/2022

2/1/2022

12/21/2021

12/9/2021

Investment Stage

Growth Equity

Other

Other

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$3.02M

$99M

$99M

Note

Acquired

Acquired - II

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

3

8

10

10

BD Partners & Customers

10 Partners and customers

BD has 10 strategic partners and customers. BD recently partnered with Accelerate Diagnostics on August 8, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

8/15/2022

Supplier

United States

BD, Accelerate Diagnostics Announce Global Commercial Collaboration

FRANKLIN LAKES , N.J. and TUCSON , Ariz. , Aug. 15 , 2022 / PRNewswire / -- BD , a leading global medical technology company , and Accelerate Diagnostics , Inc. an innovator of rapid in-vitro diagnostics in microbiology , today announced a worldwide commercial collaboration agreement where BD will offer Accelerate Diagnostics , Inc. 's rapid testing solution for antibiotic resistance and susceptibility offering results in hours , versus one to two days with some traditional laboratory methods .

6

8/15/2022

Partner

United States

Digital health news, funding roundup in the prior week; August 15, 2022

The partnership includes Bain & Company taking a minority investment in Trinity Life Sciences .

1

8/15/2022

Partner

United States

Digital health news, funding roundup in the prior week; August 15, 2022

The partnership includes Bain & Company taking a minority investment in Trinity Life Sciences .

1

6/14/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

6/9/2022

Partner

Spain

Subscribe to see more

Subscribe to see more

10

Date

8/15/2022

8/15/2022

8/15/2022

6/14/2022

6/9/2022

Type

Supplier

Partner

Partner

Partner

Partner

Business Partner

Country

United States

United States

United States

United States

Spain

News Snippet

BD, Accelerate Diagnostics Announce Global Commercial Collaboration

FRANKLIN LAKES , N.J. and TUCSON , Ariz. , Aug. 15 , 2022 / PRNewswire / -- BD , a leading global medical technology company , and Accelerate Diagnostics , Inc. an innovator of rapid in-vitro diagnostics in microbiology , today announced a worldwide commercial collaboration agreement where BD will offer Accelerate Diagnostics , Inc. 's rapid testing solution for antibiotic resistance and susceptibility offering results in hours , versus one to two days with some traditional laboratory methods .

Digital health news, funding roundup in the prior week; August 15, 2022

The partnership includes Bain & Company taking a minority investment in Trinity Life Sciences .

Digital health news, funding roundup in the prior week; August 15, 2022

The partnership includes Bain & Company taking a minority investment in Trinity Life Sciences .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

6

1

1

10

10

BD Service Providers

1 Service Provider

BD has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P, and Acquired - II

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acq - P2P, and Acquired - II

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

BD Team

35 Team Members

BD has 35 team members, including , .

Name

Work History

Title

Status

Tom Isett

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Tom Isett

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

You May Also Like

Truvian Sciences Logo
Truvian Sciences

Truvian Sciences is a healthcare company at the intersection of diagnostics and consumer technology. Its automated benchtop system produces lab-accurate results for a full suite of health tests using a small sample of blood. Powered by patented technologies and intelligent integration, Truvian's system delivers an alternative to off-site labs, providing immediate insights to inform healthcare decisions.

S
Sight Diagnostics

Sight Diagnostics provides affordable and accurate diagnostics in a compact platform designed for use in qualified labs in low volume settings. Its proprietary machine-vision based technology provides the capability to perform multiple tests on a single, easy-to-operate platform.

Torus Biosystems Logo
Torus Biosystems

Torus Biosystems performs testing of DNA for scientific and medical research purposes.

A
Accellix

Accellix develops fully automated, cost-effective, actionable cell-based analysis, 24/7 at the point of need, to a broad range of users. Its Accellix single-use cartridge analysis system provides results in less than 30 minutes, requires minimal training, and does not require users to deal with biological reagents, sample preparation, and complex data analysis.

Weavr Health Logo
Weavr Health

Weavr Health is dedicated to connecting people to health by simplifying sample collection and processing for healthcare.The Velvet device is designed so anyone, anywhere can easily collect high-quality samples without a phlebotomist. The Velvet device offers a smooth experience of blood self-collection for patients. It leverages a similar experience to traditional glucose testing, which >25% of people have experienced. Each device arrives with all that is needed to collect, package and ship quality samples to the lab for a convenient experience.

C
Cardea Bio

Cardea Bio is a mass producer of biocompatible semiconductors, also called the BPU™ (Biosignal Processing Unit). The BPU is a semiconductor capable of translating real-time streams of multiomics signals into digital information. Through the BPU™ platform, Cardea's long-term vision is to democratize access to the biosignals and insights behind the most advanced technology on the planet: nature and biology. Cardea Bio was founded in 2013 and is based in San Diego, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.